EraCal Therapeutics Ltd

Swiss Biotech Association

Member

The biotech startup EraCal Therapeutics Ltd. develops a novel anti-obesity drug with superior efficacy and safety in zebrafish, mice, and rats compared to the standard of care. Our zebrafish-based phenotypic platform enabled new target discovery and is applicable to other indications.

Cooperation possibilities

In vivo drug discovery and/or validation, CNS active compounds, small molecule chemistry.

Location

Wagistrasse 13, Schlieren, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2018
Number of employees in Switzerland

1-9

Key business

Core competencies

You may also be interested in

SIX

The Swiss Stock Exchange, representing more than a third of the European life sciences market capitalization and accounting for around 35% of the total market capitalization (as of 7 April 2021), the exchange is one of Europe’s leading listing venues for biotech companies.
Zürich

Not a member

Laevoroc Oncology AG

Founded in 2019, Laevoroc is a privately-owned, Swiss oncology group of companies that leverages word-class technologies, our oncology expertise and extensive R&D and commercial experience to approach innovation in cancer therapeutics in a way that combines the pragmatic with the visionary.
Hünenberg

Member

Rowestil Consulting GmbH

Expertise in exploratory clinical drug/diagnostic development is available across a number of disease areas. Timing of input into the developmental strategy from regulatory and commercial perspectives is important in moving development programs towards success.
6318 Walchwil

Member